Ortho Clinical Diagnostics targets sepsis threat with its VITROS B•R•A•H•M•S PCT assay, as COVID-19 patients run the risk of bacterial coinfections & adverse outcomes.
In the wake of COVID-19, it has been observed that the clinical course of adult inpatients may include sepsis, acute cardiac injury or acute kidney injury among others. Biochemical monitoring of COVID-19 patients through in vitro diagnostic testing is critical for assessing disease severity and progression as well as monitoring therapeutic intervention.
VITROS® B•R•A•H•M•S PCT (Procalcitonin) Assay has been recently launched by Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, in India. VITROS® B•R•A•H•M•S PCT (Procalcitonin) assay can help clinicians for the early detection and differential diagnosis of clinically relevant bacterial infections; the assessment of the degree of severity and the prognosis of the outcome of systemic bacterial infection, sepsis, severe sepsis and septic shock and in antibiotic stewardship program in the treatment process. Ortho’s newest assay is available on the VITROS® 3600 Immunodiagnostic System, VITROS® 5600 and VITROS® XT 7600 Integrated Systems and VITROS® ECi/ECiQ Systems.
Dangers of Sepsis among COVID-19 patients:
1. Sepsis is a life-threatening clinical condition caused by the body’s extreme response to infection.
2. If unrecognized or untreated, it can lead to systemic inflammation, tissue damage and organ failure or death.
3. Sepsis is estimated to affect more than 30 million people globally each year, potentially leading to six million deaths.
4. Sepsis was the most frequently identified complication among COVID-19 patients followed by respiratory failure, ARDS, Heart failure and Septic shock, resulting in mortality.
How VITROS® B•R•A•H•M•S PCT helps:
The VITROS® B•R•A•H•M•S PCT assay can aid clinical assessment in the early detection of severe bacterial infections (sepsis, community-acquired pneumonia, acute bronchitis, and acute exacerbation of chronic obstructive pulmonary disease) and in making decisions regarding antibiotic therapy. Emerging antibiotic resistance has made it extremely important to reduce the unnecessary and prolonged use of antibiotics.
Ortho Clinical Diagnostics has also recently introduced two COVID-19 Antibody Tests with 100% specificity that helps to identify previously exposed individuals, who have developed antibodies to SARS-CoV-2 (COVID-19 virus). “Because Every Test Is a Life, Ortho Clinical Diagnostics is committed to providing medical teams with high-quality diagnostics that deliver accurate results that help clinicians treat their patients faster.” -says Ravi Sinha, Country Director- India / Other SAARC Countries, Ortho Clinical Diagnostics.
For details contact :
+91-9820572151; +91-9773525507; +91-844031077
covid19connect@orthoclinicaldiagnostics.com
